Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1670930 | 0.97 | CCR1 (1.00) | CCR1KCNH2ADRB1CYP3A4 | |
| SCHEMBL1670283 | 0.90 | CCR1 (0.82) | CCR1KCNH2ADRB1CYP3A4 | |
| SCHEMBL1671030 | 0.89 | CCR1 (0.81) | CCR1KCNH2ADRB1CYP3A4 | |
| SCHEMBL12799891 | 0.89 | CCR1 (0.79) | CCR1KCNH2ADRB1CYP3A4 | |
| SCHEMBL1671219 | 0.89 | CCR1 (0.79) | CCR1KCNH2ADRB1CYP3A4 | |
| SCHEMBL1670293 | 0.89 | CCR1 (0.79) | CCR1KCNH2ADRB1CYP3A4 | |
| SCHEMBL1670759 | 0.88 | CCR1 (0.79) | CCR1KCNH2ADRB1CYP3A4 | |
| SCHEMBL1670500 | 0.87 | CCR1 (0.77) | CCR1KCNH2ADRB1CYP3A4 | |
| SCHEMBL1670683 | 0.86 | CCR1 (0.76) | CCR1KCNH2ADRB1CYP3A4 | |
| SCHEMBL1670335 | 0.86 | CCR1 (0.75) | CCR1KCNH2ADRB1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622906-B2 | Treatment and prognosis of pancreatic cancer | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2026-05-12 | — | — | US | disclosed |
| US-20250000800-A1 | METHODS OF PREPARING DOSAGE FORMS USING 3D PRINTING CONTAINING AMORPHOUS SOLID DISPERSIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-01-02 | — | — | US | disclosed |
| US-20240108639-A1 | COMPOSITIONS AND METHODS OF MAKING COCRYSTALS USING DIELECTRIC HEATING WITH DISPERSIVE AND DISTRIBUTIVE MIXING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-04-04 | — | — | US | disclosed |
| US-20230338300-A1 | PHARMACEUTICAL COMPOSITION CONTAINING COCRYSTALS FOR ADDITIVE MANUFACTURING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-10-26 | — | — | US | disclosed |
| EP-4259143-A1 | COMPOSITIONS AND METHODS OF MAKING COCRYSTALS USING DIELECTRIC HEATING WITH DISPERSIVE AND DISTRIBUTIVE MIXING | Board of Regents, The University of Texas System (US) | 2023-10-18 | — | — | EP | disclosed |
| US-20230218533-A1 | 3D LASER SINTERING PROCESSES FOR IMPROVED DRUG DELIVERY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-07-13 | — | — | US | disclosed |
| EP-4196110-A1 | PHARMACEUTICAL COMPOSITION CONTAINING COCRYSTALS FOR ADDITIVE MANUFACTURING | Board of Regents, The University of Texas System (US) | 2023-06-21 | — | — | EP | disclosed |
| US-20230167181-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MANUFACTURE USING THERMALLY CONDUCTIVE EXCIPIENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-06-01 | — | — | US | disclosed |
| WO-2023086832-A1 | METHODS OF PREPARING DOSAGE FORMS USING 3D PRINTING CONTAINING AMORPHOUS SOLID DISPERSIONS | BOARD OF REGENTS, THE UNIVERSITY OFTEXAS SYSTEM (US) | 2023-05-19 | — | — | WO | disclosed |
| EP-4164618-A1 | 3D LASER SINTERING PROCESSES FOR IMPROVED DRUG DELIVERY | Board of Regents, The University of Texas System (US) | 2023-04-19 | — | — | EP | disclosed |
| EP-4076528-A1 | TREATMENT AND PROGNOSIS OF PANCREATIC CANCER | Cambridge Enterprise Limited (GB) | 2022-10-26 | — | — | EP | disclosed |
| CN-115003334-A | Treatment and prognosis of pancreatic cancer | 剑桥企业有限公司 | 2022-09-02 | — | — | CN | disclosed |
| WO-2022125869-A1 | COMPOSITIONS AND METHODS OF MAKING COCRYSTALS USING DIELECTRIC HEATING WITH DISPERSIVE AND DISTRIBUTIVE MIXING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022036290-A1 | PHARMACEUTICAL COMPOSITION CONTAINING COCRYSTALS FOR ADDITIVE MANUFACTURING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-02-17 | — | — | WO | disclosed |
| US-9056858-B2 | Indazole and pyrazolopyridine compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-16 | — | — | US | disclosed |
| US-9056858-B2 | Indazole and pyrazolopyridine compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-16 | — | — | US | disclosed |
| US-20120270870-A1 | Indazole and Pyrazolopyridine Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120270870-A1 | Indazole and Pyrazolopyridine Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| WO-2011049917-A1 | INDAZOLE AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011049917-A1 | INDAZOLE AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622906-B2 | Treatment and prognosis of pancreatic cancer | PDCD1, CD274, CCR1 | CCR1 3/4885KCNH2 2506/4885ADRB1 723/4885 |
| US-20240108639-A1 | COMPOSITIONS AND METHODS OF MAKING COCRYSTALS USING DIELECTRIC HEATING WITH DISPERSIVE AND DISTRIBUTIVE MIXING | HPSE, DSC1, PRNP | CCR1 4071/4885KCNH2 1583/4885ADRB1 4290/4885 |
| US-20120270870-A1 | Indazole and Pyrazolopyridine Compounds As CCR1 Receptor Antagonists | CCR1, CCRL2, CCR3 | CCR1 1/4885KCNH2 979/4885ADRB1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.